NP-10679 is under clinical development by NeurOp and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NP-10679’s likelihood of approval (LoA) and phase transition for Ischemic Stroke took place on 10 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 10 Dec 2021 increased NP-10679’s LoA and PTSR for Subarachnoid Hemorrhage.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NP-10679 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NP-10679 overview

NP-10679 is under development for neuronal protection in brain ischemia and subarachnoid hemorrhage. It is administered through intravenous route. The drug candidate is a small molecule which targets NR2B-specific N-methyl-D-aspartate (NMDA) receptor.

NeurOp overview

NeurOp is a biotechnology company that develops medicines for the treatment of central nervous system (CNS) disorders. Its CNS drug development pipeline includes N-methyl-D-aspartate (NMDA) receptor blocker which are used for the treatment of CNS disorders including depression, neuropathic pain, ischemia (stroke)and Subarachnoid Hemorrhage (SAH). NeurOp develops pH-sensitive NMDA receptor antagonists for large clinical trials in humans suffering from ischemic events such as stroke. The company improves its drug research and development capabilities by forming consulting relationships with specialists in neuropharmacology, toxicology, drug chemistry, and pre-clinical and clinical studies. NeurOp is headquartered in Atlanta, Georgia, the US.

Quick View NP-10679 LOA Data

Report Segments
  • Innovator
Drug Name
  • NP-10679
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
Key Developers
  • Sponsor Company: NeurOp
  • Originator: Emory University
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.